重组人血管内皮抑制素联合FOLFOX4方案治疗中晚期胃癌临床疗效观察及安全性

Analysis of clinical efficacy and serum tumor antigen level change of endostar combined with FOLFOX4 program for advanced gastric cancer

目的探讨重组人血管内皮抑制素注射液(恩度)联合FOLFOX4方案治疗中晚期胃癌的临床疗效及安全性。方法将53例中晚期胃癌患者随机分为观察组31例和对照组22例,观察组采用恩度联合FOLFOX4方案治疗,对照组采用FOLFOX4方案。对比2组临床疗效、血清肿瘤标志物水平变化及不良反应。结果治疗3个月后观察组有效率为58.06%高于对照组的31.82%,差异有统计学意义(P<0.05)。治疗前2组患者血清癌胚抗原(CEA)、糖类抗原50(CA50)、糖类抗原125(CA125)、糖类抗原153(CA153)、糖类抗原199(CA199)水平无显著差异(P>0.05),治疗后2组患者血清CEA、CA50、CA125、CA153、CA199水平均显著降低,且观察组血清CEA、CA50、CA125、CA153、CA199水平低于对照组,差异均有统计学意义(P<0.05)。2组患者胃肠道反应和骨髓抑制发生率较高,但2组比较差异无统计学意义(P>0.05)。结论恩度联合FOLFOX4方案对中晚期胃癌的临床有效,不良反应均可耐受,是一种安全有效的治疗方案,值得临床推广。

Objective To investigate the clinical efficacy and safety of endostar combined with FOLFOX4 program for advanced gastric cancer. Methods 53 cases with advanced gastric cancer were randomly divided into observation group 31 ca-ses and control group 22 cases. Observation group treated with endostar combined with FOLFOX4 program,control group was treated with FOLFOX4 program. Compared sclinical effect,serum tumor marker levels and the adverse reactions of two groups. Results After 3 months＆#39;treatment,the total effective rate of observation group was 58. 06% higer than 31. 82% of control group,the difference was statistically significant（P ﹤ 0. 05）. Compared with control group,observation group of serum CEA, CA50,CA125,CA153,CA199 levels were significantly reduced（P ﹤ 0. 05）. Compared between the two groups,the adverse re-action rate had no significant difference（P ﹥ 0. 05）. Conclusion Endostar combined with FOLFOX4 program for advanced gastric cancer is effective,and well tolerated,which is a safe and effective therapy method,and worthy of clinical promotion.